The M1/M4 agonist xanomeline, in combination with the peripheral anticholinergic trospium, is effective for acute treatment of schizophrenia: results of a Phase 2 RCT comparing KarXT vs placebo
Characterizing the Efficacy and Safety Profile of the Novel Muscarinic Agonist KarXT (Xanomeline/Trospium): Primary and Secondary Results from a Phase 2 Placebo-Controlled Trial in Schizophrenia
KarXT (xanomeline, a muscarinic agonist plus trospium, a peripheral muscarinic antagonist) is superior to placebo in patients with schizophrenia: Phase 2 clinical trial results
